Novo Nordisk Rejects Claim It Influences GLP-1 Market
Pharmaceutical giant Novo Nordisk told a Texas federal judge that it does not control the GLP-1 market and has not attempted to crush its competition in a bid to dismiss an...To view the full article, register now.
Already a subscriber? Click here to view full article